Add Yahoo as a preferred source to see more of our stories on Google. Are Americans paying nearly $500 for an inhaler that would cost just $7 overseas? U.S. Sen. Tammy Baldwin, D-Wis., says there is a ...

A U.S Senate committee sent letters to four top pharmaceutical companies announcing an investigation into the high prices the companies are charging for inhalers. The Senate committee, in a letter to ...

Active ingredients of dual-action Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol now delivered by new propellant-free inhaler RIDGEFIELD, Conn., Oct. 10, 2011 /PRNewswire/ - ...

COMBIVENT RESPIMAT (ipratropium bromide and albuterol) propellant-free MDI by Boehringer Ingelheim Boehringer Ingelheim announced that the FDA has approved Combivent Respimat (ipratropium bromide and ...

Ipratropium bromide 20mcg, albuterol 100mcg (equivalent to 120mcg albuterol sulfate); per actuation; inhalation spray; CFC-free. Based on studies, ipratropium bromide appears to inhibit vagally ...

As part of the company's commitment to chronic obstructive pulmonary disease (COPD) patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare ...

Boehringer Ingelheim Pharmaceuticals, Inc. announced that the US Food and Drug Administration (US FDA) has approved Combivent Respimat, a new, propellant-free inhaler product that uses a slow-moving ...

Are Americans paying nearly $500 for an inhaler that would cost just $7 overseas? U.S. Sen. Tammy Baldwin, D-Wis., says there is a vast difference in the cost of prescriptions in the United States and ...

Statement: “Big drug companies charge as little as $7 for an inhaler overseas and nearly $500 for the exact same one here in the US.” Are Americans paying nearly $500 for an inhaler that would cost ...

COMBIVENT MDI and COMBIVENT RESPIMAT are the only short-acting bronchodilator products that offer two different medicines in a single inhaler. Clinical studies in patients with COPD have shown that ...

Experts say a key reason why inhaler prices remain so high in the U.S. is that there is very little generic competition. The Senate committee, in a letter to the pharma CEOs, cited an online global ...